Codexis, Inc. (CDXS) Stock AnalysisCDXSCodexis, Inc.

Codexis, Inc. is a provider of enzymatic solutions. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high-performance enzymes and other classes of proteins. The Company utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) and other RNA-based therapeutics through an enzymatic route. The Company also uses the CodeEvolver platform technology to develop enzymes for the synthesis of RNAi therapeutics through its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing. It operates in the Healthcare sector (INDUSTRIAL ORGANIC CHEMICALS industry).

Codexis Inc is not a good buy right now. The current price is $1.59, and the stock has seen a 36.65% decline over the past year, indicating significant underperformance. Additionally, the RSI is at 43.53, suggesting the stock is nearing oversold territory but not quite there yet. The recent public offering at $1.50 per share reflects weak demand and has negatively impacted investor sentiment, causing a drop of 20% after the announcement. The main risk is the ongoing insider selling, which has increased by 150.31% over the last month, indicating a lack of confidence from those closest to the company.

4 analysts cover CDXS: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 6.00.